Date: 2016-10-06
Type of information: Nomination
Compound:
Company: Gemphire Therapeutics (USA - Mich)
Therapeutic area: Liver diseases - Hepatic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On October 6, 2016, Gemphire Therapeutics announced the appointment of Lee Golden as Chief Medical Officer, effective October 5, 2016. In this newly-created role, Dr. Golden will be responsible for advancing the global clinical development of gemcabene, Gemphire’s product candidate.
- Dr. Golden began his industry career at Pfizer as a Medical Director on the global Lipitor team, where his responsibilities included overseeing multinational cardiovascular trials. While at Pfizer, he also served as the Medical Team Lead for filing and launch of eplerenone (Inspra) for Congestive Heart Failure and sildenafil (Revatio) for Pulmonary Arterial Hypertension. He has served in various senior leadership roles at Novartis Pharmaceuticals, Elan Pharmaceuticals and Actelion Pharmaceuticals US. He also worked as Global Therapeutic Head for Cardiovascular and Hematology at Eisai, where he managed multiple development programs including atopaxar. Most recently, Dr. Golden was Senior Vice President and Therapeutic Area Head at Mesoblast, where he developed and implemented global strategies from the pre-clinical to registration stages across cardiovascular, CNS and pulmonary therapeutic areas for Mesoblast’s proprietary cell therapy, rexlemestrocel-L. Dr. Golden received his M.D. from the New York University School of Medicine and his B.S. from the University of Michigan.
Financial terms:
Latest news:
Is general: Yes
